Clinical trials
Breast cancer clinical trials
Cancer that forms in the cells of the breast, the most common cancer in women. We’re tracking 2,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06315868Recruiting
Breast cancer organoid study for tumor analysis
This study is testing a new way to understand your breast cancer by growing tiny tumor samples (called organoids) in the lab. It will help researchers learn more about your cancer type and could lead to better treatments.
RomaAges 18–70 - NCT05800132Recruiting
AI helps review routine breast mammograms for screening
This study tests whether an artificial intelligence (AI) system can help a second reader interpret routine breast screening mammograms. It may improve how consistently images are assessed, especially when the first reader calls them normal or benign.
AubagneAges 50–74 - NCT07784660Enrolling by invitationPhase 1
Imaging breast cancer with a new tracer
This trial tests a new imaging agent that may help doctors see breast cancer more clearly. The test uses a radioactive tracer that attaches to a protein on cancer cells, which could help plan your treatment.
Tomsk, Tomsk RegAges 18–80 - NCT07743827Recruiting
Olanzapine-based steroid-sparing anti-nausea treatment for breast cancer
This trial tests a new anti-nausea medicine combination for breast cancer patients getting AC chemotherapy, specifically designed for those with diabetes, obesity, or other metabolic issues. It aims to reduce the need for steroids, which can be riskier for these patients.
Alexandria, Alexandria GovernorateAges 18–70 - NCT07721753Recruiting
Online exercise and therapy for breast cancer mood
This study tests an online program that combines fun video-game exercises with talk therapy to help breast cancer patients who feel depressed or anxious. It takes place in Malaysia and is for Chinese-speaking adults.
Xinxiang, HenanAges 18 years+ - NCT06642948Recruiting
AI system for exercise rehab in breast cancer survivors
This study tests a new AI-based skeleton recognition system to guide rehabilitation exercises for breast cancer survivors. It may help reduce pain and improve mobility for those taking aromatase inhibitors.
ShanghaiAges Any age - NCT07557654Recruiting
Breast Cancer Detection on Chest CT Scans
This study tests whether routine chest CT scans—imaging done for other reasons—can reliably find breast cancer. Researchers will compare chest CT results with mammograms and/or breast MRI to see if this approach could catch breast cancers earlier without extra imaging.
ShanghaiAges 18 years+ - NCT07469267Recruiting
Armpit radiation vs more surgery for early breast cancer with node spread
This trial tests whether radiation to the lower armpit (level I-II axilla) works as well as more extensive surgery for women with early-stage breast cancer that has spread to one or two sentinel lymph nodes (with cancer size > 2 mm). It aims to find a gentler treatment that still keeps the cancer from coming back.
Guiyang, GuizhouAges 18 years+ - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07395336RecruitingPhase 2
Elacestrant and exemestane for HR+/HER2- breast cancer that has spread
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Milan, ItalyAges 18 years+ - NCT07244094Recruiting
AI predicts breast cancer spread risk from tissue scans
This trial uses artificial intelligence to analyze images of your tumor tissue to predict if breast cancer might spread to other parts of the body. It may help doctors better understand your individual risk and guide treatment decisions.
Changchun, JilinAges 18–95 - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT07130383RecruitingPhase 2
Study of two experimental drugs for advanced breast cancer and other solid tumors
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07131735Recruiting
AI detection of breast cancer during surgery
This trial tests a device that analyzes the smoke from surgical tools during breast cancer surgery. Artificial intelligence detects cancer in real time to help doctors remove all the tumor.
Santiago, Santiago CentroAges 18 years+ - NCT07120087Recruiting
Online program to lower breast cancer risk for high-risk women
This trial tests an online program that teaches women at high risk of breast cancer how to lower their risk. If you were part of the MyPeBS study and found to have high risk, this program might help you take steps to protect your health.
LyonAges 40–74 - NCT07104266RecruitingPhase 2
Celecoxib for early triple-negative breast cancer
This research study tests whether adding a drug called celecoxib (an anti-inflammatory pill) can help treat early-stage triple-negative breast cancer after surgery, before or during radiation therapy. You may be eligible if your cancer was removed cleanly and you do not have other health issues like stomach ulcers, kidney problems, or a history of allergic reactions to certain pain relievers.
Sherbrooke, QuebecAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07038785Recruiting
Can trained dogs find breast cancer from breath?
This trial will see if specially trained dogs can identify breast cancer by smelling breath samples. You would give a breath sample and the dogs will be tested on how well they can detect cancer from it.
Totowa, New JerseyAges 18 years+ - NCT06992882RecruitingPhase 3
Comparing two chemo regimens with Herceptin for early breast cancer
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06953882RecruitingPhase 2
Skipping chemo after surgery for ER+ HER2- breast cancer
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06416293Recruiting
Improving breast cancer care with patient input
This trial aims to improve breast cancer care by working together with patients and doctors. It is for people with breast cancer or DCIS (a very early stage), and your input will help shape better care.
Augsburg, BavariaAges 18 years+ - NCT04874064Recruiting
AI blood tests for triple-negative breast cancer after treatment
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
London, OntarioAges 18 years+
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer?
- Yes. Clin2 currently lists 2,417 recruiting breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.